PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10964013

Statistical methods for analyzing repeated measures.

D Ghosh·T A Deisher·J L Ellsworth
View original source ↗Export metadata ↓

Abstract

Repeated measurements arise frequently in biomedical research. In many situations, the scientific question of interest concerns finding differences in the measurements between groups. This question is frequently addressed by using analysis of variance-type methods that fail to incorporate information regarding the repeated sampling design of the experiment. In this paper, we provide an introduction to nonstatisticians of two approaches for analyzing such data. The procedures can be performed by using available software. These methods are illustrated on data from a preclinical study conducted by ZymoGenetics.

Explore related subjects

Angiotensin-Converting Enzyme InhibitorsAnimalsBlood PressureData Interpretation, StatisticalDobutamineDose-Response Relationship, DrugEnalaprilMaleModels, StatisticalMyocardial InfarctionRatsRats, Sprague-DawleyStatistics as TopicVentricular Function, LeftJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Ghosh, T A Deisher, J L Ellsworth. 1999. Statistical methods for analyzing repeated measures.. https://doi.org/10.1016/s1056-8719(00)00066-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.

BACKGROUND: Pulmonary arterial hypertension (PAH) is associated with structural changes in the pulmonary vasculature characterized by the proliferation of cellular components of the vessels. ACE inhibitor (ACEI) may have beneficial effects in treating PAH, but its precise mechanism of action in the remodeling process is unclear. p21 is a cyclin-dependent kinase inhibitor that may have a protective role in this process by inhibiting cellular proliferation. Endothelial nitric oxide synthase (eNOS) has also been shown to be protective by its vasodilatory effect. Therefore, we investigated whether expression of p21 and eNOS was modulated by ACEI treatment in a rat model. METHODS AND RESULTS: Monocrotaline (MCT) was administered to 2 groups of Sprague-Dawley rats fed a high-cholesterol diet, ie, one group received MCT concomitantly with enalapril treatment (MCT(+)/ACEI(+) rats), and the other group did not receive enalapril (MCT(+)/ACEI(-) rats). After 5 weeks, MRI showed right ventricular hypertrophy in MCT(+)/ACEI(-) rats. MCT(+)/ACEI(+) rats showed a preserved right ventricular morphology. Isolated pulmonary perfusion studies showed that ACEI significantly upregulated NO production, as measured by nitrite levels. Addition of N-methyl-D-glucamine dithiocarbamate-Fe solution, an NO-trapping agent, reversed the basal vasodilatory effect of ACEI in the pulmonary vasculature. Immunoblot analysis showed decreased p21 and eNOS expression in the lung in MCT(+)/ACEI(-) rats, whereas their expression was preserved with enalapril treatment. CONCLUSIONS: ACEI suppresses the development of MCT-induced PAH in rats. The mechanism of action might involve the preservation of p21 and eNOS expression. Both p21 and endothelium-derived NO appear to have protective roles in the development of PAH.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2001

Atrial natriuretic peptide mimetics and vasopeptidase inhibitors.

There is now substantial evidence supporting a role of the natriuretic peptides as a major defence mechanism against excess salt and water retention and high blood pressure. Because of this there has been considerable interest in the therapeutic potential of the natriuretic peptide system. Several approaches have been explored including the use of native peptides, the development of natriuretic peptides mimetics and targetting of endogenous clearance of natriuretic peptides. While ANP and BNP administration may be valuable in some circumstances, however, the limitations of the use of peptides especially for long-term treatment are well apparent. In view of this, considerable effort has been devoted to the development of orally active agents to enhance endogenous natriuretic peptides through inhibition of breakdown by neutral endopeptidase. This research has now led to the vasopeptidase inhibitors - dual inhibitors of both endopeptidase and angiotensin converting enzyme. These agents clearly provide a novel approach to enhance endogenous natriuretic peptide function on a background of reduced angiotensin II activity and may lead to an important advance in the treatment of hypertension and of conditions associated with overt salt and water overload.

Angiotensin-Converting Enzyme Inhibitors↗